Cancer Clinical Trial
— GenePNSOfficial title:
Genomic Profile and Tumor Immune Attack in Paraneoplastic Neurological Syndromes (PNS)
Verified date | May 2019 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that
can affect any part of the central or peripheral nervous system.
PNS occurs at the intersection between immune system and the tumor, where a combination of
genetical and environmental factors may play a role.
Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely
unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover,
a better understanding of the biological mechanisms underlying PNS would allow a more precise
identification of the modalities that permit PNS patients to have a better oncological
prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology.
To this effect, an extremely innovative approach involves directly exploring the tumoral
tissue of patients suffering from specific PNS via genomic and transcriptomic analysis.
The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to
the generation of PNS.
In the present study, the investigators will analyze the salient features of tumors
associated with PNS, namely the histological and immune cells infiltrate characteristics,
their transcriptomic profile, and mutational status of involved antigens.
Status | Active, not recruiting |
Enrollment | 980 |
Est. completion date | January 1, 2022 |
Est. primary completion date | January 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - presence of well characterized antibodies in serum or cerebrospinal fluid; - histologically proven cancer with available tumour sample; - Paraneoplastic neurological syndrome (PNS) diagnosis according to the international guidelines; - Age: at least 18 years old. Exclusion Criteria: - Absence of complete clinicopathological data |
Country | Name | City | State |
---|---|---|---|
France | Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes | Lyon |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of mutations in cancer genes coding for onconeural proteins and inflammatory response mediators. | Genetic alterations in tumors associated with Paraneoplastic neurological syndromes (PNS) | 36 months | |
Secondary | Proportion of different immune cells in the tumor's immune infiltrate | Histological immune infiltrate characteristics | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|